1 September 2024

Starpharma receives $3.7M R&D tax incentive refund

Melbourne, Australia; 22 February 2018: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has received a $3.7M R&D tax incentive refund associated with FY17 expenditures. The refund relates to eligible R&D expenditure across Starpharma’s portfolio, including VivaGel® and DEP® programs.

The R&D tax incentive is a flagship program in the Australian Government’s innovation agenda. The program encourages companies like Starpharma to engage in R&D activities to develop world-class technology with the potential to significantly benefit global health outcomes.

Commenting on the refund, Starpharma CEO Dr Jackie Fairley said: “Starpharma is highly supportive of the R&D tax incentive program and we believe that it has been a significant driver of innovation in Australia and has assisted Starpharma to advance its dendrimer technology into late-stage and commercial products. The refund enables the Company to further build its portfolio, including clinical stage products - DEP® docetaxel and DEP® cabazitaxel.”

Download ASX Announcement: Starpharma receives $3.7M R&D tax incentive refund  (pdf file, 126kb)

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.